Triomics automates oncology workflows with GenAI powered platform, raises $15M

–News Direct–

Currently, oncology staff must manually search thousands of patient health records to find the right trials or care pathways for their patients. Triomics is today announcing it has raised $15M to help cancer centers streamline these workflows and process oncology data at scale by applying their framework to build, institution-tuned large language models (OncoLLM) and use case-specific software. The company has raised from several Silicon Valley firms making pioneering investments in generative AI and healthcare, including Lightspeed, Nexus Venture Partners, General Catalyst and Y Combinator.

Manual chart review can take hours per patient, and many health systems face significant backlogs in completing key oncology-related workflows for thousands of patients. This workload leads to clinical delays, such as patients missing out on clinical trials or biomarker-driven treatments, lagging quality reporting, and provider dissatisfaction and turnover.

Triomics software automates screening a patient according to a clinical trial's inclusion and exclusion criteria, and citing the medical record as evidence
Triomics software automates screening a patient according to a clinical trial's inclusion and exclusion criteria, and citing the medical record as evidence

Triomics co-founders Sarim Khan (CEO) and Hrituraj Singh (CTO) were college friends who later worked as an MIT biotech researcher and Adobe AI researcher, respectively. They knew software existed to quickly analyze the ~20% of medical data that is stored in a uniform, structured manner, like a patients demographics or laboratory values. However, they realized recent advances in generative AI created the possibility of similarly analyzing the ~80% of medical data that exists in an unstructured format, like a doctors free-text note.

Triomics co-founders: Sarim Khan and Hrituraj Singh
Triomics co-founders: Sarim Khan and Hrituraj Singh

Hrituraj and I decided to partner to build solutions leveraging the advances in the field of generative AI and LLMs to help hospital staff, said Sarim Khan, CEO of Triomicss. We want our solutions to reason and sound like experts in oncology.

After developing an OncoLLM with Medical College of Wisconsin researchers, Triomics found that, in just minutes, it found 90% of eligible patients for clinical trials, which would have taken days or weeks for qualified nurses. It also extracted structured data points from unstructured notes at similar or higher accuracy to proprietary models like GPT4 or Claude while being 40 times cheaper. Triomics recently also published the results of its information retrieval engine for oncology, which they found to be 1.5-2 times better than other state-of-the-art retrieval models.

Most of the solutions on the market today claim they use GenAI, but many lack published evidence. Triomics is setting themselves apart by taking a truly collaborative approach to co-developing these models, said Bradley Taylor, Chief Research Informatics Officer at the Medical College of Wisconsin and Director of the CTSI Center for Biomedical Informatics.

Anai Kothari, a surgical oncologist at the Medical College of Wisconsin Cancer Center added: The ability to quickly and accurately convert complex cancer data into a format that can be used to improve patient care is crucial. Triomics has been a great partner in integrating our suggestions and rigorously studying their approach to ensure safety.

OncoLLM powers proprietary Triomics software that integrates with health system EHRs to complete specific clinical and administrative tasks. For example, Triomics Prism aids in patient-trial matching by prescreening oncology patients with upcoming appointments to find relevant clinical trials. Triomics Harmony curates EHR data to support quality reporting, cohort analysis and precision oncology.

Hrituraj Singh, CTO at Triomics, commented: Our investments in our core areas of focus have been deliberate. We have successfully merged expertise in two complex functional areas: our AI researchers, who are specialized in customizing language models to specific domains, and our clinical staff, who have decades of oncology-specific experience. As a result, our software can complement the strengths of these advanced models while also proactively addressing potential flaws, all with the intricacies of cancer research and care in mind.

Given the heightened importance of accuracy for oncology data, Triomics partners with leading academic cancer centers and researchers to develop generative AI performance and safety benchmarks and best practices. Partners include the Collaboration for Oncology-focused LLM Training (COLT), a consortium of leaders from a dozen NCI-designated cancer centers, and the Cancer Informatics for Cancer Centers (CI4CC) Society.

We differentiate ourselves by building tailored models specifically for oncology and pairing them with GenAI native workflows, said Sarim Khan. While other solutions address some of the use cases were working on, like patient-trial matching, they are broad based solutions that use or modify legacy technologies that have proven not to have the scalability or ROI the industry is requesting.

Triomics next plans to publish additional data on OncoLLM efficacy across a diversity of settings and patient populations, and develop software that powers additional use cases.

Triomics is leveraging existing healthcare datasets and Generative AI to empower hospital staff to automate clinical trials and streamline cancer center workflows, said Dev Khare, partner at Lightspeed. We are excited to back Triomics in this important mission.

With robust early results for their proprietary oncology specific LLMs and partnerships with leading cancer care and research centers, Triomics is well poised to deliver significant value to cancer care providers and patients in the U.S. and globally, said Jishnu Bhattacharjee, managing director at Nexus Venture Partners. We are thrilled to partner with Sarim and Hrituraj to help build a remarkably impactful company!"

About Triomics

Triomics uses generative AI to streamline workflows for cancer centers. Its oncology specialized generative AI model (OncoLLMTM) and use case-specific software help cancer providers process free-text health record data at scale, match patients to clinical trials, improve quality of care operations, deliver precision oncology and more. Based in San Francisco, the company has raised $15 million from leading VC investors.

About Lightspeed

Lightspeed is a global multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, Health, and Fintech sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 500 companies globally including Affirm, Acceldata, Carta, Cato Networks, Darwinbox Epic Games, Faire, Innovaccer, Guardant Health, Mulesoft, Navan, Netskope, Nutanix, Rubrik, Sharechat, Snap, OYO Ultima Genomics and more. Lightspeed and its global team currently manage $25B in AUM across the Lightspeed platform, with investment professionals and advisors in the U.S., Europe, India, Israel, and Southeast Asia.

About Nexus Venture Partners

Nexus Venture Partners is a leading early-stage venture capital firm partnering with extraordinary entrepreneurs to build product-first companies. With $2.6 billion under management, Nexus operates as one team across the US and India. Nexus portfolio includes Apollo.io, Aryaka, Clover Health, Delhivery, Druva, FingerprintJS, Hasura, H2O.ai, Infra Market, Kaltura, Mezi, MinIO, Observe.ai, Postman, Pubmatic, Quizizz, Rancher, Sibros, Snapdeal, TileDB, Turtlemint, Unacademy, and Zomato.

Contact Details

Triomics

Bilal Mahmood

+44 7714 007257

b.mahmood@stockwoodstrategy.com

Company Website

https://www.triomics.com/

View source version on newsdirect.com: https://newsdirect.com/news/triomics-automates-oncology-workflows-with-genai-powered-platform-raises-15m-880658330

Triomics

comtex tracking

COMTEX_452130285/2655/2024-05-09T13:17:08

Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Brite View Research journalist was involved in the writing and production of this article.